Understanding how immunotherapy and radiation work together for cervical cancer
Immunogenomic predictors of outcomes in patients with locally advanced cervical cancer treated with immunotherapy and chemoradiation
This project aims to find better ways to predict which patients with advanced cervical cancer will respond best to a combination of immunotherapy and chemotherapy with radiation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11133049 on NIH RePORTER |
What this research studies
For patients with locally advanced cervical cancer, current treatments often aren't enough, especially when cancer has spread to lymph nodes. This project looks at how the body's immune system and tumor cells change when patients receive immunotherapy alongside chemotherapy and radiation. Researchers are examining blood and tumor samples to understand why some patients respond well and others don't. The goal is to discover new ways to combine these treatments more effectively and identify markers that predict better outcomes, ultimately improving patient care.
Who could benefit from this research
Good fit: Patients with locally advanced cervical cancer who are receiving or have received immunotherapy combined with chemotherapy and radiation would be ideal candidates.
Not a fit: Patients with early-stage cervical cancer or those not undergoing immunotherapy and chemoradiation may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to more personalized and effective treatment plans for patients with advanced cervical cancer, improving their chances of long-term survival.
How similar studies have performed: While previous trials combining these treatments have shown mixed results, this project seeks to address critical knowledge gaps by examining immune responses and optimal treatment sequencing.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Zamarin, Dmitriy — Icahn School of Medicine at Mount Sinai
- Study coordinator: Zamarin, Dmitriy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.